Developer of genomic-based cancer diagnostic platform. It offers a platform technology based on a non-invasive blood test that captures the unmodified locations of the genome and analyzes the changes that occur during cancer. The company was founded in 2020 and headquartered in Birmingham, United Kingdom. It has raised $8.4M in series a funding, with backing from Calculus Capital, Illumina Ventures, IQ Capital, Agilent, and others. The company operates in the Life Sciences - Oncology, Life Sciences - Genomics, Life Sciences - Clinical Genomics space. Its offerings span Oncology - In-Vitro Diagnostic Tests - Diversified. The company's offerings encompass Oncology - In-Vitro Diagnostic Tests - Diversified.
← All startups
Tagomics
Series ADeveloper of genomic-based cancer diagnostic platform. It offers a platform technology based on a non-invasive blood test that captures the unmodified locations of the genome and analyzes the changes that occur during cancer. The company was founded in 2020 and headquartered in Birmingham, United Kingdom. It has raised $8.4M in series a funding, with backing from Calculus Capital, Illumina Ventures, IQ Capital,…
About
Business model
Oncology > In-Vitro Diagnostic Tests > Diversified,
Genomics > Applied Genomics > Clinical Genomics > Diagnostics > Sequencing-based > Genetic Diagnosis > Epigenomics
Institutional investors
Calculus CapitalIllumina VenturesIQ CapitalAgilentMerciaMidlands Engine Investment FundMeltwind AdvisoryOMX VenturesUkri
Latest coverage
📰 Browse funding news — rounds, valuations, and market moves for founders.
Backed by funds in our directory
🗂️ See who's investing in Life Sciences — full fund directory with check size and geography.